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Introduction: 
 
Abstract 
Background: Rheumatoid Arthritis  is a systemic inflammatory disease characterized 
by  chronic and erosive polyarthritis  .it is  the most common inflammatory arthritis , 
affecting from 0.5-1% of the general population. 
Dyslipidemia is a quite important problem in Rheumatoid Arthritis  (RA) patient, 
which causes morbidity and mortality. As known, dyslipidemia is one of 
atherosclerosis  risk-factor, and main mortality cause of longstanding RA patient. 
Objectives: are to measure Prevalence of dyslipidemia in patients with Rheumatoid 
Arthritis compared with healthy control peoples and to find out correlations 
between Dyslipidemia and disease activity in patients with Rheumatoid Arthritis.  
 Patients and Methods: A total of one hundred patients with RA ( 80 female and 20 
male )were included in the study, they were attending Consultation  clinic and 
division of Rheumatology in the General Medical Teaching Hospital in Slemani city 
from (October 2015 to September 2016)  who fulfilling the 2010 American College of  
Rheumatology/European league against Rheumatism classification criteria for RA 
and one hundred healthy  age and  sex-matched controls. Fasting lipid profiles of 
cases and control were estimated after an overnight fast of 12 hours. Association 
between lipid profile and disease activity using disease activity score DAS 28, 
inflammatory markers (CRP and ESR) was also determined.   
Results: RA patients showed a higher prevalence of associated dyslipidemia (48%) in 
comparison to control (4%) p- value less than 0.001. 
Our result showed a significant reduction in serum high density lipoproteins (HDL) p-
value less than 0.001, with significant elevation of serum total cholesterol, 
triglyceride, low density lipoprotein and very low density lipoprotein p-value 
0.001,0.007,0.01and 0.5  respectively in comparison to controls. 
there is a significant association between dyslipidemia and high DAS 28 score 
(p=0.02). 
there is  a significant association between high ESR of RA patients and dyslipidemia 
(p=0.001). A significant association was observed between high CRP level and RA 
patients with no dyslipidemia (p<0.001). 
Conclusion: Dyslipidemia are frequent among the patients with rheumatoid arthritis 
and highly associated with active RA. Serum HDL significantly reduced while other 
parameters of lipid profiles significantly increased in comparisons to control.   
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 Introduction : 
Rheumatoid arthritis (RA) is a chronic systemic 
inflammatory disease   characterized by  chronic 
and erosive polyarthritis 
(1)
,  associated with 
persistent inflammatory synovitis  , progressive 
joint destruction , and an excess mortality when  
compared to the general population .
 (2.3). 
It is characterized by symmetric erosive 
synovitis 
(3)
. Female are 2.5 times more likely 
to be affected than male
 (4)
.  
 The onset of disease can occur at any age but 
peak incidence occurs within fourth and fifth 
decade of life 
(5) 
Its clinical diagnosis made on the basis of 
symptoms, physical examinations, X-ray and 
laboratory investigations 
(6)
. 
Patients with RA have an increased mortality 
when compared with age-matched controls, 
primarily due to cardiovascular disease. This 
is most marked in those with severe disease, 
with reduction in expected life span by 8-15 
years 
(7)
. 
 Dyslipidemia are being increasingly 
recognized as an important contributory 
factor toward the development of 
cardiovascular disease 
(8)
.  
Premature cardiovascular disease (CVD) is 
very common in RA patients 
(9, 10)
. RA is 
associated with 50% increase in incidence of 
myocardial infarction (MI) and cardiovascular 
diseases as compared to general population 
(10)
. 
It has been observed that increased 
inflammation and active disease has an 
impact on lipid patterns in blood 
(11)
. 
Atherosclerosis is now considered as an 
inflammatory disease as it is a result of 
inflammation and inflammatory cytokines are 
prevalent in atherosclerotic plaques 
(12,13)
. 
Although dyslipidemia in RA may be 
partially governed by a genetic predisposition, 
it is also influenced by an array of other 
factors including disease activity 
(14)
, reduced 
physical activity secondary to pain, disability 
(14)
, and drug therapy 
(15-17)
.  
 Dyslipidemia is highly prevalent in RA 
affecting between 55-65% of patients 
(18,19)
 and 
can manifest in RA patients with both early 
(20)
 
and advanced disease
 (21)
. The Disease Activity 
Score 28 (DAS28) is a major scoring system for 
evaluating disease activity of RA.  In clinical 
practice CRP and ESR are used in monitoring 
disease activity and response to the treatment. 
CRP.
 (22) 
Patients and methods 
 Study design and setting: A prospective 
case control was done   
This study was conducted at 
Rheumatology Unit, outpatient clinic in 
Sulaimani Teaching Hospital, Sulaimani  
city. The study was carried out over 12 
months from October 2015 to September 
2016.  
 
Sampling 
 
This study included one hundred  patients  
with RA ( 80 female and 20 male 
)fulfilling the 2010 American College of 
Rheumatology/European league against 
Rheumatism classification criteria for RA 
and one hundred healthy sex and  age-
matched controls. 
patients and controls' age were between 
20-70 years old. 
Exclusion criteria: 
History of smoking or patients suffering from 
condition that affect the lipid profile such as 
Diabetus mellitus, Hypertension, Ischemic 
heart disease, renal impairment, liver and 
thyroid functional abnormalities, Cushing 
syndrome and obesity (BMI >30) were 
excluded. 
Also any patients received medications 
affecting lipid metabolism such as beta 
blocker, diuretics, cyclosporine, oral 
contraceptive pills (OCP), patients who 
received oral or intra-articular steroid till one 
month before study and pregnant women were 
excluded. 
 
The study protocol: 
  The study protocol includes:-
(Questionnaire, clinical examination of 
RA patients,  ,Disease Activity Score 
(DAS 28), Laboratory investigations) 
-Laboratory investigations include : 
(ESR),(RFT), (LFT), (TSH), (FBS or 
RBS), (ECG), lipid  profile 
.immunological tests, (CRP), (ACCP) . 
 
 The body mass index (BMI) was also measured 
for all patients 
 
Questionnaire: 
 
A protocol was designed to obtain data about 
the name, age, occupation, residence of the 
patients, weight, height, and drug history, 
duration of the disease, history of chronic 
disease, and history of smoking, number of 
tender and swollen joints. The results of 
investigations (RF, ESR, CRP, lipid profile, 
RFT, LFT, TFT, and ACCP) were recorded on 
the same questionnaire .. 
 analyses: Statistical  
All patients' data entered using computerized 
statistical software; Statistical Package for 
Social Sciences (SPSS) version 17 was used. 
Descriptive statistics presented as (mean ± 
standard deviation) and frequencies as 
percentages. Kolmogorov Smirnov analysis 
verified the normality of the data set. Multiple 
contingency tables conducted and appropriate 
statistical tests performed, Chi-square used for 
categorical variables and Fishers exact test was 
used when more than 20% of the cells less 
than 5. In all statistical analysis, level of 
significance (p value) set at ≤ 0.05 and the 
result presented as tables and/or graphs. 
Statistical analysis of the study was done by 
the community medicine specialist.  
Results 
A total 100 rheumatoid arthritis (RA) 
patients were included in present study 
with mean age of as 57±8.6 years, 36% of 
them were 50-59 years age. Females were 
more than males with female to male ratio 
as 4:1.  
 
 Age distribution of RA patients.  
 
 
Gender distribution of RA patients. 
Disease duration distribution of RA 
patients 
RA disease duration of studied patients, 
52% of them had disease duration of more 
than 5 years 
 
 
Mean DAS 28 score of RA patients was 
5.3±1.9, 46% of RA patients had 
moderate score and 35% of RA patients 
had high score\ 
 
 
 
DAS 28 scores distribution of RA 
patients. 
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Mean cholesterol level of RA patients was 
174.5±42.8 mg/dl, 27% of them had high 
cholesterol level. Mean triglycerides level 
of RA patients was 132.1±56.4 mg/dl, 
37% of RA patients had high Tg level. 
Mean LDL level of RA patients was 
101.9±39.5 mg/dl, 18% of RA patients 
had high LDL level. Mean VLDL level of 
RA patients was 29.8±14.8 mg/dl, 38% of 
RA patients had high VLDL level. Mean 
HDL level of RA patients was 55±18.6 
mg/dl, 38% of RA patients had low HDL 
level. Dyslipidemia was detected among 
48% of RA patients.  
Lipid profile of RA patients.  
 
 
 
 
Dyslipidemia distribution of RA patients. 
 
There was a significant association 
between high cholesterol level and RA 
cases (p=0.001). High triglycerides level 
was significantly higher among RA 
patients (p=0.007). A significant 
association was observed between high 
LDL level and RA cases (p=0.01). A 
significant differences were observed 
between RA cases and controls regarding 
VLDL level (p=0.5). Low HDL level was 
significantly higher among RA cases 
(p<0.001). Generally, Dyslipidemia was 
significantly higher among RA patients 
(p<0.001).     
 
 
 
 
 
 
Dyslipidemia in RA cases and controls. 
No significant differences were observed 
between male and female RA cases 
regarding lipid profile 
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Distribution of RA patients' lipid profile 
according to gender. 
 
 
There was a significant association 
between dyslipidemia and high DAS 28 
score (p=0.02).  
 
Dyslipidemia distribution in RA disease 
activity. 
There was a significant association 
between high ESR of RA patients and 
dyslipidemia (p=0.001). A significant 
association was observed between high 
CRP level and RA patients with no 
dyslipidemia (p<0.001).  
 
Distribution of RA patients' ESR and CRP 
according to dyslipidemia of RA patients. 
discussion 
Several pieces of evidence indicate that 
rheumatoid arthritis (RA) is a 
proatherogenic disease associated with 
increased cardiovascular (CV) mortality 
 
(23)  
which account for about half of all 
deaths in these patients 
(24)  
. Besides 
genetic and traditional CV risk factors,
 (25)
 
chronic inﬂammation has effect in the 
development of this process. 
(26)
.  
Results  showed that RA occurs in all age 
groups between 20-70 years, which 
showed that 36% of them between 50 to 
59 years& 26% were between 40 to 49 
years of age; this is in accordance with 
other study which mentioned that RA 
affects usually people above 40 years old 
(27)
.and also matched with the study done 
by Abdul Qahar  ZH et al   in Baghdad, 
Iraq 2013 
(28)
. 
The prevalence of dyslipidemia among 
RA patients in present study was 48%. 
This prevalence is close to results of Haye 
Salinas MJ et al in Argentin 
 (29)
 that 
reported dyslipidemia prevalence in RA 
patients as 43%, on other hand, Akiyama 
et al study in Japan 
 (30)
 showed that 
56.5% of RA patients had dyslipidemia.
 
(31)
. 
Patients with rheumatoid arthritis (RA) 
have higher rates of morbidity and 
mortality than the general population, 
which is highly attributed to an increased 
risk of cardiovascular disease (CVD) 
among RA patients 
 (32)
. The increased 
risk of CVD appears to be linked to 
coronary atherosclerosis 
 (33)
 and may be 
directly caused by chronic inflammation 
or secondarily caused by physical 
inactivity and drugs used to treat RA 
(34)
.  
In this study we found that patients 
diagnosed with RA had significantly 
reduced levels of HDL-cholesterol in 
comparison to control groups and this 
was matched with many other study done 
in all of Pakistan 2012 by  Nisar A et al  
(35)
, Tunisia 2011 by Zrour SH et al 
(36)
, 
Malaysia 2012 by Manjunatha Goud BK  
et al 
(37)
, South India  by Vinapamula  KS 
et al 
(38)
, Saudi Arabia 2013 by Bahlas  S 
et al 
(39)
, Bagdad, Iraq 2013 by Ameer  
KH et al by Georgiadis  AN et al  
(40)
 and 
United Kingdom 2011 
(41)
 which is un 
favorable profile with regard to 
cardiovascular risks 
(42)
 and there was no 
study against it. 
 
Our study revealed a significantly higher 
cholesterol level of RA patients in 
comparison to controls (p=0.001). This is 
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consistent with Attar study in Saudi 
Arabia 
(43)
 
  
 
In present study, blood levels of 
triglycerides and LDL cholesterols of RA 
patients were significantly higher than 
healthy controls with significantly lower 
HDL cholesterol level. These findings are 
similar to results of previous Spanish 
study done by Gonzalez Gay MA  et al 
(44)
.  
Regarding HDL-cholesterol, it has been 
reported that patients with active RA 
consistently demonstrate reduced levels 
(45)
.  
Also in  our study  Serum VLDL level of 
RA patients was significantly higer than 
healthy controls. This finding coincides 
with Al-Kaissi et al study in Jordan 
(46)
 
reported high VLDL prevalence among 
RA patients.but Inconsistently with our 
results , Al-Chetachi and Shaher study 
(47)
 
in Iraq  reported no significant difference 
in VLDL and Tg levels between RA and 
healthy controls.  
In general, dyslipidemia was significantly 
Noted in RA patients in present study 
(p<0.001). This is consistent with results 
of Mahdi et al study in Iraq 
(48)
  and Curtis 
et al study in USA 
(49)
.  
In our study, the RA activity (DAS) was 
significantly high among RA patients with 
dyslipidemia (p=0.02). This is consistent 
with results of Georgiadis et al study in 
Greece 
(50)
.  
Our Results showed that ESR and CRP 
levels were significantly higher among 
RA patients with dyslipidemia. These 
findings are significant to results of Curtis 
et al study in USA 
(49)
. Inflammation is a 
common denominator in both RA and 
atherosclerosis. A growing body of 
evidence supports the involvement of 
common proinflammatory cytokines—
such as macrophage migration inhibitory 
factor (MIF), interleukin (IL)-1, IL-6, and 
tumor necrosis factor-alpha (TNF-α)—in 
the development and progression of both 
RA and atherosclerosis 
(51)
. 
 
 
Conclusions  
 The prevalence of dyslipidemia 
among rheumatoid arthritis 
patients in Sulaimani is high. 
 The blood levels of total 
cholesterol, triglycerides and LDL 
cholesterols were higher among 
RA patients. 
 HDL cholesterol level was lower 
among RA patients. 
 Dyslipidemia may be a risk factor 
for rheumatoid arthritis severity 
and cardiovascular diseases. 
 Obesity is a risk factor for 
rheumatoid arthritis incidence.  
Recommendations  
 Dyslipidemia among RA patients 
are common and this increase risk 
of cardiovascular disease and 
mortality among RA patients, 
lipid management including 
greater use of statin therapy may 
be appropriate to reduce this. 
 
 Screening programs for RA 
patients on lipid profile to predict 
activity and severity of disease, 
Cardiovascular screening should 
be recommended every 6 months 
to once yearly in Sulaimani city. 
 Encouraging the diet restriction 
programs and physical activities in 
schools to prevent the obesity. 
 Further national large sized studies 
on prevalence and effect of 
hyperlipidemia on RA patients 
must be supported. 
 Additional prospective, long-term 
studies are needed to 
comprehensively determine the 
role of inflammation and the 
impact of biologics on lipid levels 
and cardiovascular outcomes in 
patients with RA. 
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